FDA-cleared profile

DeepXray

Alpha Intelligence Manifolds, Inc. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: DeepXray is a fully automated CR or DX radiographic image-processing device intended to aid trained medical professionals in measuring minimum joint-space width, assessing sclerosis, joint-space narrowing, and osteophytes under OARSI criteria, and assessing radiographic knee osteoarthritis under Kellgren-Lawrence grading of standing fixed-flexion knee radiographs. It must not replace full patient evaluation or be relied on alone for diagnosis.

Clinical role
Automated knee radiograph measurement and osteoarthritis feature assessment to aid professional review.
Images and patients
X-ray/Radiography · Knee; radiographic osteoarthritis features
Key limitation
Keep in mind: The software must not replace full patient evaluation or be relied on alone for diagnosis; quality control may withhold results and professional review remains required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: DeepXray is a fully automated CR or DX radiographic image-processing device intended to aid trained medical professionals in measuring minimum joint-space width, assessing sclerosis, joint-space narrowing, and osteophytes under OARSI criteria, and assessing radiographic knee osteoarthritis under Kellgren-Lawrence grading of standing fixed-flexion knee radiographs. It must not replace full patient evaluation or be relied on alone for diagnosis.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Knee; radiographic osteoarthritis features Input: Computed or directly digital standing, fixed-flexion knee radiographs in CR or DX format.
  • Who uses it?Intended users: Trained radiologists, orthopedists, physicians, and medical technicians.
  • What does the software produce?Output: Minimum joint-space width, femoral-tibial angle, Kellgren-Lawrence grade, OARSI feature assessments, quality warnings, and an editable web report.
  • What is its most important limitation?Key limitation: The software must not replace full patient evaluation or be relied on alone for diagnosis; quality control may withhold results and professional review remains required.

Clinical takeaway. Clinical role: DeepXray is a fully automated CR or DX radiographic image-processing device intended to aid trained medical professionals in measuring minimum joint-space width, assessing sclerosis, joint-space narrowing, and osteophytes under OARSI criteria, and assessing radiographic knee osteoarthritis under Kellgren-Lawrence grading of standing fixed-flexion knee radiographs. It must not replace full patient evaluation or be relied on alone for diagnosis.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports clinical performance validation on an independent test dataset from one OAI clinical site: 6,125 knee radiographs from 1,121 individuals, with ground truth established by multiple physicians following adjudication. For KL Grade ≥2, sensitivity was 0.87 (95% C.I. 0.86/0.88) and specificity 0.84 (0.83/0.85); sensitivity and specificity were also reported for joint space narrowing, osteophyte and sclerosis. Orthogonal regression slopes against OAI reference measurements were 1.02 (medial mJSW), 0.98 (lateral mJSW) and 0.97 (femoral-tibial angle). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
DeepXray is a fully automated CR or DX radiographic image-processing device intended to aid trained medical professionals in measuring minimum joint-space width, assessing sclerosis, joint-space narrowing, and osteophytes under OARSI criteria, and assessing radiographic knee osteoarthritis under Kellgren-Lawrence grading of standing fixed-flexion knee radiographs. It must not replace full patient evaluation or be relied on alone for diagnosis.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Automated knee radiograph measurement and osteoarthritis feature assessment to aid professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Computed or directly digital standing, fixed-flexion knee radiographs in CR or DX format.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Minimum joint-space width, femoral-tibial angle, Kellgren-Lawrence grade, OARSI feature assessments, quality warnings, and an editable web report.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical radiographic review workflows using supported standing knee radiographs.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained radiologists, orthopedists, physicians, and medical technicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The software must not replace full patient evaluation or be relied on alone for diagnosis; quality control may withhold results and professional review remains required.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports clinical performance validation on an independent test dataset from one OAI clinical site: 6,125 knee radiographs from 1,121 individuals, with ground truth established by multiple physicians following adjudication. For KL Grade ≥2, sensitivity was 0.87 (95% C.I. 0.86/0.88) and specificity 0.84 (0.83/0.85); sensitivity and specificity were also reported for joint space narrowing, osteophyte and sclerosis. Orthogonal regression slopes against OAI reference measurements were 1.02 (medial mJSW), 0.98 (lateral mJSW) and 0.97 (femoral-tibial angle). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DeepXray’s clinical performance validation was performed on an independent test dataset using data from one of the five clinical sites of the Osteoarthritis Initiative (OAI), a multicenter longitudinal study. This test dataset comprised of 6,125 knee radiographs, representing 1,121 individuals," … "ground truth labeling of Kellgren-Lawrence grades as well as osteophyte, sclerosis, and joint space narrowing grades according to the OARSI criteria, and measurements of the minimum joint space width and femoral-tibial angle were established in the OAI study by multiple physicians following adjudication procedures". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports clinical performance validation on an independent test dataset from one OAI clinical site: 6,125 knee radiographs from 1,121 individuals, with ground truth established by multiple physicians following adjudication. For KL Grade ≥2, sensitivity was 0.87 (95% C.I. 0.86/0.88) and specificity 0.84 (0.83/0.85); sensitivity and specificity were also reported for joint space narrowing, osteophyte and sclerosis. Orthogonal regression slopes against OAI reference measurements were 1.02 (medial mJSW), 0.98 (lateral mJSW) and 0.97 (femoral-tibial angle). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DeepXray’s clinical performance validation was performed on an independent test dataset using data from one of the five clinical sites of the Osteoarthritis Initiative (OAI), a multicenter longitudinal study. This test dataset comprised of 6,125 knee radiographs, representing 1,121 individuals," … "ground truth labeling of Kellgren-Lawrence grades as well as osteophyte, sclerosis, and joint space narrowing grades according to the OARSI criteria, and measurements of the minimum joint space width and femoral-tibial angle were established in the OAI study by multiple physicians following adjudication procedures". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone sensitivity for KL Grade ≥2 on 11775 knees/1121 subjects: 0.87 (95% C.I. 0.86/0.88); joint space narrowing (OARSI Grade ≥1): 0.88 (0.87/0.89); osteophyte (OARSI Grade ≥1): 0.86 (0.85/0.87).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DeepXray Result Sample Number Performance Metric Output (95% C.I.) Sensitivity Kellgren- 11775 knees/ 0.87 (0.86/0.88) (KL Grade ≥2) Lawrence 6114 DICOM/ Grade 1121 subjects" … "Sensitivity 11775 knees/ 0.88 (0.87/0.89) Joint Space (OARSI Grade ≥1) 6114 DICOM/ Narrowing". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Standalone specificity for KL Grade ≥2 on 11775 knees/1121 subjects: 0.84 (95% C.I. 0.83/0.85); joint space narrowing (OARSI Grade ≥1): 0.82 (0.81/0.83); osteophyte (OARSI Grade ≥1): 0.80 (0.79/0.81).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DeepXray Result Sample Number Performance Metric Output (95% C.I.) Sensitivity Kellgren- 11775 knees/ 0.87 (0.86/0.88) (KL Grade ≥2) Lawrence 6114 DICOM/ Grade 1121 subjects Specificity 0.84 (0.83/0.85) (KL Grade ≥2)" … "Joint Space (OARSI Grade ≥1) 6114 DICOM/ Narrowing Specificity 1121 subjects 0.82 (0.81/0.83) (OARSI Grade ≥1)". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Kellgren-Lawrence grade sensitivity

0.87 proportion

  • EndpointSensitivity for KL grade >= 2
  • Population11,775 knees from 6,114 DICOM studies and 1,121 subjects
  • Tested versionDeepXray configuration described in K223621

Kellgren-Lawrence grade specificity

0.84 proportion

  • EndpointSpecificity for KL grade >= 2
  • Population11,775 knees from 6,114 DICOM studies and 1,121 subjects
  • Tested versionDeepXray configuration described in K223621

Joint-space narrowing sensitivity

0.88 proportion

  • EndpointSensitivity for OARSI grade >= 1
  • Population11,775 knees from 6,114 DICOM studies and 1,121 subjects
  • Tested versionDeepXray configuration described in K223621

Joint-space narrowing specificity

0.82 proportion

  • EndpointSpecificity for OARSI grade >= 1
  • Population11,775 knees from 6,114 DICOM studies and 1,121 subjects
  • Tested versionDeepXray configuration described in K223621

K223621 FDA evidence package for DeepXray

  • DesignFDA 510(k) performance evaluation using a longitudinal Osteoarthritis Initiative test dataset with adjudicated labels and reference measurements.
  • PopulationKnee; radiographic osteoarthritis features
  • Scopeexact submission
  • Tested versionDeepXray configuration described in K223621
  • Samplen=1121
  • IndependenceSponsor or vendor study

K223621

The FDA summary also reports osteophyte and sclerosis metrics and measurement regressions; four status metrics are promoted here to keep the dossier concise. The source states that automated quality control blocked 0.3% of test samples.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K223621 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Computed or directly digital standing, fixed-flexion knee radiographs in CR or DX format.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) K223621: DeepXray

  2. Routing

    Source context, not route validation: The FDA package describes CR or DX radiograph input, DICOM viewing beside the original radiograph, a browser-based editable report, quality warnings, markup images, and saved or output reports.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) K223621: DeepXray

  3. AI processing

    Source context, not route validation: The FDA package describes operation in Docker containers on a Linux server with a web-browser report; current hosting, security, service, availability, and local deployment remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) K223621: DeepXray

  4. Returned objects

    Source context, not route validation: Minimum joint-space width, femoral-tibial angle, Kellgren-Lawrence grade, OARSI feature assessments, quality warnings, and an editable web report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) K223621: DeepXray

  5. Viewer/worklist/report

    Unresolved route: Minimum joint-space width, femoral-tibial angle, Kellgren-Lawrence grade, OARSI feature assessments, quality warnings, and an editable web report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) K223621: DeepXray

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes operation in Docker containers on a Linux server with a web-browser report; current hosting, security, service, availability, and local deployment remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package describes CR or DX radiograph input, DICOM viewing beside the original radiograph, a browser-based editable report, quality warnings, markup images, and saved or output reports.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only trained radiologists, orthopedists, physicians, and medical technicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K223621 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The software must not replace full patient evaluation or be relied on alone for diagnosis; quality control may withhold results and professional review remains required.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K223621 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The FDA package describes operation in Docker containers on a Linux server with a web-browser report; current hosting, security, service, availability, and local deployment remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes CR or DX radiograph input, DICOM viewing beside the original radiograph, a browser-based editable report, quality warnings, markup images, and saved or output reports.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The software must not replace full patient evaluation or be relied on alone for diagnosis; quality control may withhold results and professional review remains required.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K223621 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The software must not replace full patient evaluation or be relied on alone for diagnosis; quality control may withhold results and professional review remains required.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. knee radiograph osteoarthritis analysis software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223621
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Knee; radiographic osteoarthritis features
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-09-08
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
12Source classes checked
5Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Five PubMed records were screened. Two concern the different DeepXray Spina bone-density product and three are unrelated legacy uses of the phrase deep X-ray; none evaluates the K223621 knee-osteoarthritis product and version, so all five are quarantined. The current discovery snapshot contains 5 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K223621: DeepXray

    U.S. Food and Drug Administration - Published 2023-09-08 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. DeepXray model card (K223621)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K223621 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253172

MediAI-OA

Crescom Co., Ltd.

Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.

Modality
X-ray/Radiography
Anatomy
Knee joint
Decision
2026-06-15
FDA-cleared K253930

Overjet Iris Intelligent Imaging System

Overjet, Inc.

Authorized purpose: Overjet Iris is a web-based dental PACS for storing, viewing, and supporting image-quality review of two-dimensional intraoral radiographs, panoramic images, and color photographs.

Modality
X-ray/Radiography
Anatomy
Teeth and maxillofacial anatomy
Decision
2026-04-10
FDA-cleared K250525

Second Opinion® Panoramic

Pearl, Inc.

Authorized purpose: Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth; caries, periapical radiolucency, and impacted third molars
Decision
2025-11-14
FDA-cleared K251002

Videa Dental AI

VideaHealth Inc.

Authorized purpose: Analyzes bitewing, periapical, and panoramic intraoral radiographs from patients aged 3 years and older to identify and localize specified suspected dental findings, historical treatments, and normal anatomy; diagnostic use remains with trained dental professionals.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-09-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history